IgM-Enriched Immunoglobulin for Neonatal Sepsis

Status Not yet recruiting

Clinical Trial Summary

This study compares giving prophylactic IgM enriched Intravenous Immunoglobulin (IVIG) with placebo in 1 hour after birth, in neonates with risk factors of Early-Onset Neonatal Sepsis (EONS). In addition to the intervention, standard regimen antibiotics are also given within 1 hour. The IVIG is given for 3 days and primary and secondary outcomes will be collected. Risk factors are both from maternal and neonate origin.

Clinical Trial Description

This randomized-controlled trial conducted in Cipto Mangunkusumo Hospital, Jakarta, Indonesia aims to determine the efficacy of prophylactic IgM-Enriched IVIG in preventing EONS. A total of 70 very low birth weight (VLBW) neonates with risk factors for EONS including maternal factors of premature rupture of membrane (PROM), fever, urinary tract infection (UTI), chorioamnionitis, and neonatal factor of prematurity and resuscitation history will be collected. These neonates within 1 hour of life will then be administered either placebo or IgM-enriched IVIG 0.25g/kg/day for 3 days, in addition to first-line empiric antibiotic. Randomization is done using simple randomization. Triple masking (Participant, Investigator, Outcomes Assessor) is conducted.

These neonates will then be clinically observed and evaluated for early mortality (mortality below 7 days), hemodynamics, length of stay, blood culture results, C-Reactive Protein (CRP), IT ratio, routine hematological examination, and IgGAME as parameters of improvement and prevention of EONS.

STATA version 12 (Macintosh version) will be used for data management and statistical analyses. The variables will first be presented descriptively, continued with bivariate and multivariate analysis. Bivariate analysis will be conducted between independent and dependent variables using chi-square/Fisher's exact test, Student's t-test, and Kruskal-Wallis. Variables with p-values <0.25 will be included in the multivariate analysis using logistic regression. The investigators will use two-sided p-values in our analysis with a p < 0.05 level of significance. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04041765
Study type	Interventional
Source	Fakultas Kedokteran Universitas Indonesia
Contact	Rinawati Rohsiswatmo, MD, PhD
Phone	+62811133094
Email	rinarohsis@gmail.com
Status	Not yet recruiting
Phase	Phase 3
Start date	September 2019
Completion date	August 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03995979` - Inflammation and Protein Restriction	N/A
Completed	`NCT03255187` - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution	N/A
Completed	`NCT04507867` - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III	N/A
Completed	`NCT03577223` - Egg Effects on the Immunomodulatory Properties of HDL	N/A
Completed	`NCT04383561` - Relationship Between LRG and Periodontal Disease	N/A
Active, not recruiting	`NCT03622632` - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed	`NCT06216015` - Exercise Training and Kidney Transplantation	N/A
Completed	`NCT04856748` - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed	`NCT05529693` - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population	N/A
Recruiting	`NCT05670301` - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases	N/A
Recruiting	`NCT05415397` - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs	Phase 3
Recruiting	`NCT05775731` - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting	`NCT04543877` - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study	Early Phase 1
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Completed	`NCT03429920` - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors	N/A
Completed	`NCT06065241` - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.	N/A
Completed	`NCT05864352` - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed	`NCT03318731` - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males	N/A
Not yet recruiting	`NCT06134076` - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota	N/A
Not yet recruiting	`NCT05910489` - Micro and Nanoplastics in Greenhouse Workers: Biomarkers of Exposure and Effect

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.